PRESENTATION

Q4 2020 — Presentation

Q4 2020PDF · 21 pages1.3 MB
Merck
Q4 2020 Earnings

-- 1 of 21 --

Forward-looking statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
2
This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive
the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties
materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and
currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry
regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability
to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk;
dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent
litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2019
Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site
(www.sec.gov).

-- 2 of 21 --

$12.5B
+5%
Q4 performance highlights
3
Advanced
the
pipeline
1. Growth rates exclude impact of foreign exchange
2. The GAAP to non-GAAP reconciliation is available in the Supplemental Tables to Merck’s Q4 2020 earnings release.
3. GAAP EPS =$(0.83)
Delivered
worldwide
sales
growth 1
• 	Invested $2.6B in research and development, making
significant progress in advancing our pipeline and across
our key growth pillars
• 	Returned $1.5B to shareholders through dividends
• 	Continued to capitalize on value-enhancing business
development, including the acquisition of VelosBio and
OncoImmune
$1.32
+17%
Strong
non-GAAP
EPS
growth 1
Created
shareholder
value
• 	Received 2 FDA approvals for KEYTRUDA, and FDA accepted
with priority review a Supplemental Biologics License
Application for KEYTRUDA
• 	Ex-U.S., received 1 approval for KEYTRUDA and 2 approvals
for Lynparza in Europe, and 3 new approvals for Lynparza in
Japan
• 	Progressed COVID-19 therapeutic candidate programs,
advancing molnupiravir and acquiring MK-7110 from
OncoImmune
• 	Announced or presented data at key medical meetings,
including in HIV, vaccines and oncology

-- 3 of 21 --

Driving value for patients and shareholders by progressing our pipeline
Key 2020 regulatory milestones
• 	In the U.S.:
• 	Received FDA approvals across oncology (KN-204, KN-158, KN-177, KN-629 R/M,
TMB-H, Q6W dosing, PAOLA-1, PROfound, NF-1, KN-057, KN-355, KN-146), vaccines
(GARDASIL9), hospital (RECARBRIO for HABP/VABP), and neuroscience (BELSOMRA
data in Alzheimer’s Disease)
• 	FDA accepted filings for KEYTRUDA (KN-522), granted priority review for KEYTRUDA
based on KN-590, and vericiguat1 , granted breakthrough designation for belzutifan
(MK-6482) and Fast Track designation for V181
• 	Announced supply agreement with U.S. Government for COVID-19 treatment
candidate, MK-7110
• 	In the EU, received approvals in oncology (PAOLA-1, POLO and PROfound) and received
CHMP positive opinions in oncology (KN-1773 )
• 	In Japan, received approvals for KEYTRUDA (KN-181 and Q6W dosing), Lynparza (PAOLA-1,
PROfound and POLO) and SILGARD9
• 	In China, received approval for KEYTRUDA (KN-181 and KN-048) and Lenvima monotherapy
(DTC)
• 	ERVEBO approved in African Nations of DRC, Burundi, Ghana and Zambia
Key 2020 data presentations & readouts
• 	Presented new data across our broad portfolio of assets at key medical meetings including in
oncology, HIV, vaccines and respiratory, and new data from novel mechanisms including
vibostolimab (TIGIT), MK-4830 (ILT4), quavonlimab (CTLA4) and belzutifan (HIF2α)
• 	Toplined results and awaiting presentation from pivotal phase 3 trials in oncology (KN-775
and KN-581), vaccines (PNEU-WAY and PNEU-FLU) and respiratory (COUGH-1 and COUGH-
2)
• 	Advanced pipeline assets and presented data including vibostolimab, belzutifan,
quavonlimab, LAG3 (MK-4280), CD27 (MK-5890), STING (MK-1454), V116, V117 and
islatravir
4
1. Announced FDA approval for vericiguat (Verquvo) on January 20, 2021
2. Announced that the FDA accepted for priority review the Biologics License Application for V114 for use in adults on January 12, 2021
3. Announced European Commission approval for KEYTRUDA based on KN-177 on January 26, 2021
4. Announced CHMP positive opinion for KEYTRUDA based on KN-204 on February 1, 2021

-- 4 of 21 --

COVID-19 research efforts: advanced therapeutic candidates
5
Treatment candidates
Molnupiravir
(MK-4482)
MK-7110
(CD24Fc)
Collaboration with Ridgeback Bio to develop molnupiravir (MK-4482), an
orally available antiviral candidate in development for the treatment of
COVID-19.
In preclinical studies, molnupiravir has shown antiviral activity against
SARS-CoV-2, as well as the coronaviruses responsible for MERS and
SARS.
Results from Ridgeback’s Phase 1 studies are largely complete and will
read out in the coming months. Several of Ridgeback’s three small Phase 2
studies also should have data available in the next few months.
Merck’s two large pivotal Phase 2/3 trials studying molnupiravir, one in
outpatients and another in hospitalized patients with confirmed COVID-19,
have primary completion dates in May 2021, and interim efficacy data is
anticipated in the first quarter.
We have scaled production and expect to have over 10 million courses
available by the end of 2021, if approved.
MK-7110, a potentially first-in-class recombinant fusion protein acquired
from OncoImmune, in development for the treatment of patients with
severe and critical COVID-19.
We expect full Phase 3 study results in the first quarter.
If approved for use, we expect to scale up manufacturing to supply the
U.S. government with approximately 60,000-100,000 doses of MK-7110
by mid-2021 as part of the government’s pandemic response goals.

-- 5 of 21 --

Oncology: strong growth across broad portfolio
• 	KEYTRUDA sales of $4.0B increased 27% year-
over-year, reflecting continued leadership in
lung and strong growth across a broad number
of additional indications
o 	In the U.S., sales of $2.2B driven by growth
across all key tumor types, including
continued growth and leadership in lung,
continued benefit from Q6W dosing, and
momentum from launches in renal cell and
endometrial carcinomas
o 	Ex-U.S., 28% growth, driven by global
uptake in lung and launches in new tumor
types
• 	Strong growth from both Lynparza and Lenvima
continues to bolster oncology portfolio with
growth of 53% and 26%, respectively
1. All growth rates exclude the impact of foreign exchange. 	6
4Q19 	4Q20
+27% YOY
KEYTRUDA Performance
4Q19 	4Q20
Lynparza Performance
+53% YOY
4Q19 	4Q20
Lenvima Performance
+26% YOY

-- 6 of 21 --

4Q19 	4Q20
Vaccines: GARDASIL underlying demand remains intact
• 	GARDASIL sales of $1.0B increased year-over-
year and reflect continued strong underlying
demand
o 	In the U.S., sales grew year-over-year
largely due to $240M of benefit from CDC
borrowing and repayment
o 	Ex-U.S., sales declined year-over-year
driven by current wave of COVID-19
lockdowns in Europe that offset growth in
China
1. All growth rates exclude the impact of foreign exchange. 	7
+41% YOY
GARDASIL Performance

-- 7 of 21 --

Hospital: solid BRIDION growth despite reduced surgical procedures
4Q19 	4Q20
• 	BRIDION sales of $355M increased 13%
year-over-year driven by increased market
share gains, partially offset by lower elective
surgery procedures
• 	In 2020, Bridion grew 7%, representing
higher demand globally
• 	Continued strong uptake of PREVYMIS,
resulting from longer duration of therapy for
existing patients, offset by postponed
transplant procedures
1. All growth rates exclude the impact of foreign exchange.
+13% YOY
8
BRIDION Performance

-- 8 of 21 --

Animal Health: strong growth across innovative portfolio
4Q19 	4Q20
• 	Animal Health sales increased 6% to $1.2B
o 	Companion Animal sales increased 9%,
reflecting strength in vaccines and
parasiticides
o 	Livestock sales increased 4%, reflecting
an additional month of sales related to
the 2019 acquisition of Antelliq, partially
offset by distributor purchasing
patterns
• 	In 2020, Animal Health grew +10%,
demonstrating strong demand across both
the Companion Animal and Livestock
portfolios and a benefit from the 2019
acquisition of Antelliq
1. All growth rates exclude the impact of foreign exchange.
+6% YOY
9
Animal Health Performance

-- 9 of 21 --

2020: key pillars driving growth the past four years
1. All growth rates exclude the impact of foreign exchange.
2. Units in millions. 10
2017 	2018 	2019 	2020
$11,084
KEYTRUDA Performance
2017 	2018 	2019 	2020
Lynparza Performance
2017 	2018 	2019 	2020
Lenvima Performance
2017 	2018 	2019 	2020
Animal Health Performance
2017 	2018 	2019 	2020
GARDASIL Performance
2017 	2018 	2019 	2020
BRIDION Performance
$7,171
$3,809
$14,380
$187	$20
$725
$444
$149
$404
$580
$4,703
$4,393
$4,212
$3,875
$3,151
$3,737 $3,938
$2,308
$1,131 $1,198
$917
$704
N/A
+10% YOY
+6% YOY 	+7% YOY
+43% YOY	+62% YOY
+30% YOY

-- 10 of 21 --

Growth across most global markets in 2020
despite ongoing pandemic impact
United
States
Canada
Europe 2
Latin
America
Eastern Europe /
Middle East
Africa
Japan
+12%
China
Global
pharmaceutical
sales +4%1
$343M
+6%
+13% 	-8%
+6%
+3%
+1%
Asia Pacific
-4%
11
1. All growth rates exclude the impact of foreign exchange.
2. Europe primarily represents all European Union countries and the European Union accession markets.

-- 11 of 21 --

Q4 2020 financial results summary:
Delivering leverage in the P&L
Q4 2020 	Q4 2019 	Change Change
Ex-FX
Sales 	$12.5 	$11.9 	+5% 	+5%
GAAP Gross Margin 	55.8% 	69.1% 	-13% 	-13%
Non-GAAP Gross Margin 2 	73.0% 	72.6% 	+0% 	+1%
GAAP net (loss) income 1 	$(2.1) 	$2.4 	->100% 	->100%
Non-GAAP net income
that excludes certain items 1,2 	$3.4 	$3.0 	+12% 	+16%
GAAP EPS 	$(0.83) 	$0.92 	->100% 	->100%
Non-GAAP EPS that excludes
certain items 2 	$1.32 	$1.16 	+14% 	+17%
$ in billions, except EPS amounts
12
1. Net income attributable to Merck & Co., Inc.
2. Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and
trends. Management believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses
performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior
management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information
prepared in accordance with GAAP.

-- 12 of 21 --

2020 financial results summary:
Solid growth despite pandemic headwinds
2020 	2019 	Change Change
Ex-FX
Sales 	$48.0 	$46.8 	+2% 	+4%
GAAP Gross Margin 	67.7% 	69.9% 	-2% 	-2%
Non-GAAP Gross Margin 2 	74.3% 	74.9% 	-1% 	-0%
GAAP net income 1 	$7.1 	$9.8 	-28% 	-25%
Non-GAAP net income
that excludes certain items 1,2 	$15.1 	$13.4 	+13% 	+16%
GAAP EPS 	$2.78 	$3.81 	-27% 	-24%
Non-GAAP EPS that excludes
certain items 2 	$5.94 	$5.19 	+14% 	+17%
$ in billions, except EPS amounts
13
1. Net income attributable to Merck & Co., Inc.
2. Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and
trends. Management believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses
performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior
management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information
prepared in accordance with GAAP.

-- 13 of 21 --

Merck full-year 2021 guidance1
1. All estimates based on the assumption that the Organon business will be a part of Merck for all of 2021
2. GAAP Gross Margin Rate: Higher than 2020 by a low single-digit rate
3. GAAP Operating Expenses: Lower than 2020 by a low double-digit rate
4. GAAP Tax Rate: 15.0% - 16.0%
5. The GAAP to non-GAAP reconciliation is available in Merck’s Q4 2020 earnings release
6. Growth rates reflective of recast of non-GAAP P&L presentation
Guidance 	Key Assumptions
Revenue $51.8B to $53.8B
+8% to +12% (+6% to 10% ex-FX)
• 	Assumes ~2% positive FX impact
• 	Assumes ~2% negative impact due to the COVID-19
pandemic, particularly during the first half of 2021
Non-GAAP
Gross Margin Rate 2 	~77.0%
Non-GAAP
Operating Expenses3 	Increase by high single to low double-digit rate • 	Reflects increased R&D spend on COVID-19 research
programs and progression of pipeline assets
Other (Income) / Expense 	~$400M of expense
Tax Rate 4 	~15.0-16.0%
Shares Outstanding 	~2.53B
GAAP EPS 5 	$5.52 to $5.72
Non-GAAP EPS 5,6 	$6.48 to $6.68
+12% to +15% (+9% to +12% ex-FX)
• 	Assumes ~3% positive FX impact
• 	Changes to non-GAAP reporting resulted in a positive
impact of approximately $0.08
14

-- 14 of 21 --

Momentum leading up to the spinoff of Organon & Co.
15
Remain confident the transaction will
deliver significant benefits for both Merck
and Organon, and create value for Merck
shareholders
Organon will be well positioned for growth
as it nears the end of loss of exclusivity
exposure to key brands, with expected low
to mid-single digit annual revenue growth
off of a 2021 base year
Spinoff of Organon expected to be
completed in late second quarter 2021
Creating two companies
with enhanced strategic
and operational focus,
improved agility,
simplified operating
models, optimized capital
structures and improved
financial profiles

-- 15 of 21 --

Updated high level 2021 Organon guidance
Guidance 	Additional Comments
2020 Revenue 	$6.5B 	• 	Products that will comprise Organon
2021 Revenue 	$6.0B to $6.5B • 	Expected low to mid-single digit annual revenue
growth off of a 2021 base year
Non-GAAP
Operating Margin Mid-30% range as a standalone company post spinoff
• 	Expected to increase over time
• 	Reflecting additional costs Organon will incur to
operate as an independent company
EBITDA margins 	High 30% range as a standalone company post spinoff 	• 	Expected to increase over time
Debt $9.0B to $9.5B in initial debt
$8.5B to $9.0B special tax-free dividend to Merck
• 	Ample cash flow and financial flexibility for potential
business development opportunities, debt paydown
and a meaningful dividend
Dividend 	Meaningful dividend 	• 	Dividend will be incremental to Merck dividend
16
Organon will provide additional details at Investor Event prior to completion of spinoff

-- 16 of 21 --

Balanced approach to capital allocation:
Investing in the business and creating value for shareholders
Capital Investments
2020 to 2024
>$ 20B
Over 5 years, including expanding manufacturing
capacity for Oncology, Vaccines, and Animal
Health. Includes >$10B in the U.S.
Over the Past 12 Months
$0
$2
$4
$6
$8
$10
After-Tax R&D 	CapEx 	Dividends Paid 	Business
Development -
Ex Divestitures
Share
Repurchase (net
of Options
Proceeds)
$7.8
$4.7
$6.2
$10.6
$1.3
Billions
ORDER OF
PRIORITY
Commitment to the Dividend
$1.72 	$1.76 	$1.80 	$1.84 	$1.88 	$1.92
$2.20
$2.44 $2.60
$1.40
$1.70
$2.00
$2.30
2013 	2014 	2015 	2016 	2017 	2018 	2019 	2020 	2021E
Dollars per share
+11% 	+2% 	+2% +2% 	+2% 	+2%
+11%
17
+15%
• 	$9.2 billion invested in R&D ($7.8 billion after-tax)
• 	$10.6 billion spent on business development, including
acquisitions and collaborations for 4 COVID-19 vaccine and
therapeutic candidates, acquisition of VelosBio, strategic
oncology collaborations with Seagen, collaboration milestone
payments, and Animal Health deals
• 	$7.5 billion in dividend and share repurchases
o 	Remain committed to the dividend, which increased
7% in 2020
o 	Returned $1.3 billion share repurchases (excluding
option proceeds)
Balanced Capital Allocation to Invest in Growth While
Returning Cash to Shareholders Over Past 12 Months
+7%

-- 17 of 21 --

Merck has actively supplemented its pipeline and portfolio with
strategic business development
18
Oncology 	Cardiovascular,
Neurosciences & Other
Animal Health
Bolt-on acquisitions
Strategic
collaborations
& licensing
Completed 120 business development transactions in 2020

-- 18 of 21 --

Creating long-term value for patients, employees and shareholders
Anchored by our deep bench of talent
and commitment to our mission
Next 5 Years
Strong execution driving
sustainable revenue growth,
meaningful margin expansion and
accelerated bottom-line growth
5-10 Years
Rich pipeline addressing
areas of high unmet need to
drive performance over the
next 5 to 10 years
10+ Years
Revitalized discovery efforts and
increased expertise in biology to
deliver ongoing scientific
breakthroughs for decades to come
19

-- 19 of 21 --

Continuing to make progress on our ESG commitments
Access to
Health
Employees
Environmental
Sustainability
Ethics and
Transparency
Earning trust and confidence of stakeholders is critical for a company in the business of marketing and selling medicines and
vaccines
• 	Demonstrated commitment to transparency through disclosures about our business and how we operate, including issuing a multi-year report about
pricing practices
• 	Work with broad range of stakeholders to help develop and advance innovative financing and solutions that address the needs of patients
• 	Integrating the SDGs into our reporting to demonstrate our commitment to sustainable development
Executing an environmental sustainability strategy to take advantage of opportunities to reduce environmental impact
across operations and supply chain
• 	Featuring energy-conservation and water-use-reduction initiatives
• 	Reducing environmental impacts as evidenced by an EPA Green Chemistry Challenge Award four years running (seven awards overall)
• 	Purchasing electricity from renewable energy sources to reduce greenhouse gas emissions, including the launch of our first large wind virtual
power purchase agreement
• 	Collaborating with suppliers and customers to address shared needs and interests in environmentally beneficial ways
Fostering diverse and gender-balanced workforce essential to performance as a research-intensive company and to attracting most
talented scientists
• 	Offering numerous programs to engage employees and promote positive work environment (including female mentorship by female Board members)
• 	Partnering with Year Up, a nonprofit that enables low-income young adults of color to move from minimum wage to meaningful careers in just one year
• 	Increase in 2019 in women on our Board (25%), in executive roles (36%), and in management roles (43%)
• 	Recognized as a 2020 best place to work for LGBTQ equality by the Human Rights Campaign (HRC) Foundation
• 	Identified by the American Indian Science and Engineering Society (AISES) as a 50 Top STEM Workplaces for Indigenous STEM Professionals
Increasing access to health to advance Merck’s efforts to serve more patients
• 	History of making medicines and vaccines accessible and affordable through responsible pricing practices
• 	Implemented refreshed Access to Health Guiding Principles to ensure we continue to fulfill our commitment to access by focusing on the most critical issues
• 	Reaching more than 13 million women worldwide through Merck for Mothers, a $500 million initiative
• 	Through our 30+ year old MECTIZAN® Donation Program, eliminated river blindness in 4 Latin American countries and in parts of 6 African countries so far, and
eliminated lymphatic filariasis in 3 countries in Africa and the Middle East
• 	Thanks to the commitment of many collaborators across multiple sectors, ERVEBO, Merck’s vaccine for the prevention of disease caused by Zaire ebolavirus, is now
registered in eight African countries at high risk of Ebola (with additional African country registrations pending review). These registrations followed WHO
prequalification, conditional approval in the EU, and licensure in the United States.
20
Please find our 2019/2020 Corporate Responsibility Report here.

-- 20 of 21 --

Recast of 2020 non-GAAP P&L presentation1
Q1 2020 	Q2 2020 	Q3 2020 	Q4 2020 	FY 2020
Sales 	$12,057 	$10,872 	$12,551 	$12,514 	$47,994
COGS 	$2,837 	$2,533 	$3,020 	$3,222 	$11,613
PGM 	$9,220 	$8,339 	$9,531 	$9,292 	$36,381
Other (income) /
expense $169 	$74 	$35 	$95 	$376
Net income 	$3,851 	$3,368 	$4,278 	$3,210 	$14,706
EPS 	$1.51 	$1.32 	$1.68 	$1.27 	$5.79
$ in millions, except EPS amounts
21
1. Beginning in 2021, the Company will be changing the treatment of certain items for the purposes of its non-GAAP reporting. Historically, Merck’s non-GAAP results excluded the amortization
of intangible assets recognized in connection with business acquisitions but did not exclude the amortization of intangibles originating from collaborations, asset acquisitions or licensing
arrangements. Beginning in 2021, Merck’s non-GAAP results will no longer differentiate between the nature of the intangible assets being amortized and will exclude all amortization of
intangible assets. Also, beginning in 2021, Merck’s non-GAAP results will exclude gains and losses on investments in equity securities.

-- 21 of 21 --